dsm-firmenich has sold its stake in the Feed Enzymes Alliance to Novonesis for €1.5 billion, allowing both companies to better align with their strategic goals.

Information on the Target

dsm-firmenich, a leader in nutrition, health, and beauty, has announced the sale of its stake in the Feed Enzymes Alliance to its equal partner Novonesis for €1.5 billion. The stake represents approximately €300 million in total annual net sales for 2024, illustrating the robust nature of the business. This transaction allows Novonesis to maintain a long-term commercial relationship with dsm-firmenich’s Animal Nutrition & Health sector by continuing to distribute its feed enzymes through a premier premix network.

Following the acquisition, dsm-firmenich anticipates receiving around €1.4 billion net in cash after deducting transaction costs and capital gains tax. They are also expected to recognize a book profit upon the closure of this deal. The long-standing partnership between dsm-firmenich and Novonesis has proven successful, having evolved over 25 years to develop a competitive portfolio of feed enzymes tailored to the animal feed industry.

Industry Overview in the Target’s Specific Country

Switzerland, a hub for innovative agro-biotechnology, has seen significant growth in the animal feed sector driven by increasing global protein demand. As environmental pressures mount, players in this industry are focusing